Status:
COMPLETED
Study of Gemcitabine and Oxaliplatin With Radiation Therapy in Patients With Pancreatic Cancer
Lead Sponsor:
University of Michigan Rogel Cancer Center
Collaborating Sponsors:
Sanofi
Johns Hopkins University
Conditions:
Pancreatic Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
This study will examine a sequence of treatments including pre-operative chemotherapy and radiation, surgery and post-operative chemotherapy for resectable pancreatic cancer.
Detailed Description
This study will examine a sequence of treatments including pre-operative chemotherapy and radiation, surgery and post-operative chemotherapy for resectable pancreatic cancer. This research treatment w...
Eligibility Criteria
Inclusion
- Patients must have cytologic or histologic confirmation of carcinoma arising in the pancreas.
- Patients must be deemed resectable or borderline resectable based on criteria in section 4.2 prior to registration.
- Patients must have an expected life expectancy of at least 12 weeks and a Zubrod performance status of \< 2.
- Patients must have adequate organ function defined as follows: absolute neutrophil count of \> 1500/mm3, platelets \> 100,000/mm3, serum Cr \< 1.5 mg/dl, total bilirubin \< 3.0 mg/dl with relief of biliary obstruction if present (PTC tube or endobiliary stent).
- Patients must be free of other active systemic malignancy, ongoing infection, including HIV infection, or any other serious uncontrolled, concomitant systemic disorders or psychiatric condition that would interfere with the safe delivery of protocol therapy.
- Patients must be aware of the investigational nature of the therapy and provide written informed consent.
- Patients must have no history of previous chemotherapy for pancreatic cancer or any abdominal radiation therapy.
- Patients must not have used any investigational agent in the month before enrollment into the study.
Exclusion
- Patients with neuroendocrine tumors are excluded.
- Patients with preexisting peripheral neuropathy \> grade 2 are ineligible.
- Pregnant or nursing women are ineligible and patients of reproductive potential must agree to use an effective contraceptive method during participation in this trial and for 6 months after trial.
Key Trial Info
Start Date :
April 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2013
Estimated Enrollment :
71 Patients enrolled
Trial Details
Trial ID
NCT00456599
Start Date
April 1 2007
End Date
January 1 2013
Last Update
December 3 2015
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Johns Hopkins University
Baltimore, Maryland, United States, 21231
2
University of Michigan
Ann Arbor, Michigan, United States, 48109
3
Ohio State University
Columbus, Ohio, United States, 43210
4
Princess Margaret Hospital
Toronto, Ontario, Canada, M5G 2M9